2024
Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer.
Evans E, Fisher T, Mallow C, Foster A, Leonard J, Chaney M, Mekhail T, Seetharamu N, Steuer C, Saba N, Adkins D, Beck J, Algazi A, Burtness B, Baumgart M, Giampoli E, Hager S, Chay C, Spira A, Zauderer M. Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2024, 42: 2603-2603. DOI: 10.1200/jco.2024.42.16_suppl.2603.Peer-Reviewed Original ResearchHead and neck squamous cell carcinomaMyeloid suppressor cellsImmune checkpoint inhibitorsFirst-line treatmentDendritic cellsT cellsB cellsTumor biopsiesLymphoid structuresImmune cellsMetastatic head and neck squamous cell carcinomaActivity of immune checkpoint inhibitorsEfficacy of immune checkpoint inhibitorsSingle-arm open-label studyFirst-line treatment of patientsMetastatic head and neck cancerHead and neck squamous cell carcinoma tumorsImmune checkpoint inhibitor activationOn-treatment tumor biopsiesSuppression of adaptive immunityCD8+ T cellsNeck squamous cell carcinomaHead and neck cancerAnalysis of tumor biopsiesMechanism of immune enhancement
2022
A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.
Argiris A, Flamand Y, Savvides P, Johnson J, Li S, Forastiere A, Burtness B. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Journal Of Clinical Oncology 2022, 40: 6026-6026. DOI: 10.1200/jco.2022.40.16_suppl.6026.Peer-Reviewed Original ResearchOverall survivalFirst-line treatmentMedian OSPrognostic factorsHazard ratioBone/liver metastasesRM-SCCHNFirst-lineFirst-line treatment of patientsMultivariate modelMetastatic squamous cell carcinomaPhase III randomized trialRisk factorsCancer treated with chemotherapyPlatinum-based chemotherapyECOG performance statusCooperative group trialsSquamous cell carcinomaHead and neckTumor cell differentiationTreatment of patientsPrognostic scoring modelCox proportional hazards modelsProportional hazards modelPrior radiation